8:00 am Coffee & Networking

8:45 am Chair’s Opening Remarks

Maximizing Therapeutic Impact of Myeloid Cells Through Synergistic Approaches for Enhanced Targeting

9:00 am Clinical Case Study: Utilizing CAR-Macrophages for Precise Tumor Cell Eradication

9:30 am Clinical Case Study: CD40-Mediated Activation of Myeloid Cells to Drive Anti-Tumor Immunity to Enhance the Overall Anti-Tumor Effects

  • Peter Ellmark Chief Scientific Officer, Alligator Bioscience AB

10:00 am Program Partner Presentation

Synopsis

gene.PNG

10:30 am Morning Refreshments & Networking

Novel Progression in Discovery to Support the Clinic for Enhanced Patient Outcomes

11:30 am Can We Overcome Myeloid Cell Immunosuppression in Glioblastoma to Enhance Myeloid Cell Therapies?

  • David Reardon Clinical Director & Professor of Medicine, Dana-Farber Cancer Institute

12:00 pm Reverse Translational Immune Microenvironment Investigations of Isocitrate Dehydrogenase-Classified Primary & Recurrent Human Brain Tumors Identifies Anti-Glioma Phagocytic Immunomodulators

  • Pravesh Gupta Co-Chair Of Postdoctoral Association, MD Anderson Cancer Center

12:30 pm Lunch & Networking

Identifying Cancer-Specific Novel Targets for Myeloid Cells for Next Generation Advancement

1:30 pm Case Study: Single-Cell Analysis of the Tumor Myeloid Compartment to Identify Novel Therapeutic Immunomodulatory Targets

  • Roshan Kumar Senior Director of External Innovations, HiFiBio Therapeutics

2:00 pm Round Table Discussion: Innovative Strategies for Surpassing Resistance to Myeloid Checkpoint Inhibitors to Prevent Clinical Holds

2:30 pm Afternoon Break & Networking

3:15 pm HLA-SIRPa Bispecifics: A Novel Multitarget Therapeutic Strategy to Induce Potent Anti-Tumor Immune Responses

3:45 pm Panel Discussion – The Future of Developing Myeloid Cell Therapies

4:30 pm Chair’s Closing Remarks

5:00 pm End of Conference